

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

<i>Application Number</i>	10/524,956
<i>Filing Date</i>	December 15, 2005
<i>First Named Inventor</i>	Martin HENDRIX, et al.
<i>Art Unit</i>	1624
<i>Examiner Name</i>	Susanna More
<i>Attorney Docket Number</i>	01-2113

Sheet	1	of	4
-------	---	----	---

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document Number		Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code* (if known)	Publication Date MM-DD-YYYY		
/S.M./		2007/0161662 A1	07-12-2007	Martin HENDRIX, et al.	
/S.M./		2006-0111372 A1	05-25-2006	Martin HENDRIX, et al.	
/S.M./		2006/0106035 A1	05-18-2006	Martin HENDRIX, et al.	
/S.M./		2006-0100222 A1	05-11-2006	Frank-Gerhard BOSS, et al.	
/S.M./		2004/0286736 A1	12-30-2004	Frank WUNDER, et al.	
/S.M./		2007/0105876 A1	05-10-2007	Martin HENDRIX, et al.	
/S.M./		5,256,668	10-26-1993	Kuo-HOM, et al.	
/S.M./		5,002,949	3-26-1991	Steven M. PESECKIS, et al.	
/S.M./		3,732,225	05-08-1973	Hermann BREUER, et al.	
/S.M./		3,165,520	01-12-1965	Paul SCHMIDT, et al.	

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS					Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
Examiner Initials*	Cite No.¹	Foreign Patent Document Country Code - Number* - Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document		
/S.M./		CA 2 484 997 A1	04-22-2003	Bayer Cropscience AG		
/S.M./		CA 2 417 631 A1	01-29-2003	Bayer Aktiengesellschaft		
/S.M./		CA 2 438 890 A1	09-06-2002	Bayer Aktiengesellschaft		
/S.M./		CA 2 283 211 A1	09-17-1998	Bayer Aktiengesellschaft		
/S.M./		CH 396 926	01-31-1966	CIBA Aktiengesellschaft		
/S.M./		DE 2 408 906	09-19-1974	Chemische Fabrik von Heyden GmbH		
/S.M./		DE 101 56 249	05-28-2003	Bayer, AG		
/S.M./		DE 1 147 234	04-18-1963	CIBA Aktiengesellschaft		
/S.M./		EP 0 130 735 A1	01/09/1985	American Home Products		
/S.M./		GB 937,726	09-25-1963	CIBA Limited		
/S.M./		WO 02/06288 A1	01-24-2002	F. Hoffmann-La Roche AG		
/S.M./		WO 2004/018474 A1	03-04-2004	Bayer Healthcare AG		
/S.M./		WO 2004/026286 A3	04-01-2004	Bayer Healthcare AG		
/S.M./		WO 02/068423 A1	09-06-2002	Bayer Aktiengesellschaft		
/S.M./		WO 02/09713 A2	02-07-2002	Bayer Aktiengesellschaft		
/S.M./		WO 03/093269 A2	11-13-2003	Bayer Cropscience AG		
/S.M./		WO 03/041725 A2	05-22-2003	Bayer Aktiengesellschaft		
/S.M./		WO 99/41253	08-19-1999	Tularik Inc.		
/S.M./		WO 98/40384	09-17-1998	Bayer Aktiengesellschaft		
/S.M./		WO 98/10765	03-19-1998	The Board of Trustees		
/S.M./		WO 2004/026286 A2	04-01-2004	Bayer Healthcare AG		
/S.M./		WO 2004/026876 A1	04-01-2004	Bayer Healthcare AG		
/S.M./		WO 00/18758	04/06/2000	Mitsubishi Chemical Corp.		
/S.M./		WO 02/098864 A1	12/12/2002	F. Hoffmann-La Roche AG		
/S.M./		WO 95/10506 A1	04/20/1995	The Dupont Merck Pharmaceutical Company		
/S.M./		WO 2004/026286 A1	04-01-2004	Bayer Healthcare AG		
Examiner Signature	/Susanna Moore/			Date Considered	11/22/2009	

*EXAMINER: Initial if reference considered, whether or not opinion is in conformance with MPEP 800. Draw line through opinion if not in conformance and not considered. Include copy of this form with next communication to applicant.

[illegible]

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 4

Complete if Known

Application Number	10/524,956
Filing Date	December 15, 2005
First Named Inventor	Martin HENDRIX, et al.
Art Unit	1624
Examiner Name	Susanna More
Attorney Docket Number	01-2113

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/S.M./		F. Josef van der STAAY, et al., "The novel selective PDE9 inhibitor BAY 73-6691 improves learning and memory in rodents", NEUROPHARMACOLOGY, 55 (2008) pp. 908-916	
/S.M./		Edwin J. WEEBER, et al., "Molecular Genetics of Human Cognition", MOLECULAR INVENTIONS, Vol. 2, Issue 6, October 2002, pps. 376-391	
S.M./		International Search Report for International Application No. PCT/EP2004/004455 mailed September 17, 2004, 8 pages	
/S.M./		International Search Report for International Application No. PCT/EP2004/004412 mailed July 14, 2004, 6 pages	
/S.M./		International Search Report for International Application No. PCT/EP03/08979 mailed November 25, 2003, 8 pages	
/S.M./		International Search Report for International Application No. PCT/EP03/08923 mailed December 15, 2003, 6 pages	
/S.M./		International Search Report for International Application No. PCT/EP2004/006477 mailed October 27, 2004, 8 pages	
/S.M./		International Search Report for International Application No. PCT/EP2004/014872 mailed May 19, 2005, 10 pages	
/S.M./		Scott H. SODERLING, et al., "Identification and Characterization of a Novel Family of Cyclic Nucleotide Phosphodiesterases", THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 273, No. 25, Issue of June 19, 1998, pgs. 15559-15568	
/S.M./		Scott H. SODERLING, et al., "Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions", CURRENT OPINION IN CELL BIOLOGY, 2000, 12:174-179	
/S.M./		Svetlana G. ANDREEVA, et al., "Expression of cGMP-Specific Phosphodiesterase 9A mRNA in the Rat Brain", THE JOURNAL OF NEUROSCIENCE, November 15, 2001, 21(22); pgs. 9068-9076	
/S.M./		C. C. CHENG, et al., "Potential Purine Antagonist VII. Synthesis of 6-Alkylpyrazolo-[3,4-d]pyrimidines ^{10b} ", POTENTIAL PURINE ANTAGONISTS, VII, Vol. 23, February 1958, pgs. 191-200	
/S.M./		Lindsay FAWCETT, et al., "Molecular cloning and characterization of a distance human phosphodiesterase gene family: PDE11A", PNAS, Vol. 97, No. 7, March 28, 2000, pgs. 3702-3707	
/S.M./		Douglas A. FISHER, et al., "Isolation and Characterization of PDE9A, a Novel Human cGMP-specific Phosphodiesterase", THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 273, No. 25, Issue of June 19, 1998, pgs. 15559-15564	
Examiner Signature	/Susanna Moore/		Date Considered 11/22/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/524,956
Filing Date	December 15, 2005
First Named Inventor	Martin HENDRIX, et al.
Art Unit	1624
Examiner Name	Susanna More
Attorney Docket Number	01-2113

Sheet 3 of 4

NON PATENT LITERATURE DOCUMENTS

/S.M./	Douglas A. FISHER, et al., "Isolation and Characterization of PDE8A, A Novel Human cAMP-Specific Phosphodiesterase", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, Vol. 246, April 15, 1998, pgs. 570-577		
/S.M./	Sharon H. FRANCAIS, et al., "Characterization of a Novel cGMP Binding Protein from Rat Lung", THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 255, No. 2, Issue of January 25, 1980, pgs. 620-626		
/S.M./	Kotomi FUJISHIGE, et al., "Cloning and Characterization of a Novel Human Phosphodiesterase That Hydrolyzes Both cAMP and cGMP (PDE10A)", THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 274, No. 26, Issue of June 25, 1999, pgs. 18438-18445		
/S.M./	Helke GIELEN, et al., "A novel approach to amides from esters", TETRAHEDRON LETTERS, 43, 2002, pgs. 419-421		
/S.M./	Rudolf GOMPPER, et al., "Substituted dithiocarboxylic acids and ketene thioacetals", CARBOXYLIC ACID DERIVATIVES, Vol. 95, 1992, pgs. 2861-2870		
/S.M./	Peter G. GILLESPIE, et al., "Characterization of a Bovine Cone Photoreceptor Phosphodiesterase Purified by Cyclic GMP-Sepharose Chromatography", THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 263, No. 17, Issue of June 15, 1988, pgs. 8133-8141		
/S.M./	Michel GUIPPONI, et al., "Identification and characterization of a novel cyclic nucleotide phosphodiesterase gene (PDE9A) that maps to 21q22.3: alternative splicing of mRNA transcripts, genomic structure and sequence", HUM GENET (1998) 103:386-392		
/S.M./	J.M. HETMAN, et al., "Cloning and characterization of PDE7B, a cAMP-specific phosphodiesterase", PNAS, Vol. 97, No. 1, January 4, 2000, pgs. 472-476		
/S.M./	Kate LOUGHNEY, et al., "Isolation and Characterization of cDNAs Corresponding to Two Human Calcium, Calmodulin-regulated, 3',5'-Cyclic Nucleotide Phosphodiesterases", THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 271, No. 2, Issue of January 12, 1996, pgs. 796-806		
/S.M./	James E. HUETTNER, et al., "Primary Culture of Identified Neurons from the Visual Cortex of Postnatal Rats", THE JOURNAL OF NEUROSCIENCE, Vol. 6, No. 10, pgs. 3044-3060, 1986		
/S.M./	Kate LOUGHNEY, et al., "Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3',5'-cyclic nucleotide phosphodiesterase", GENE, 216 (1998), pgs. 139-147		
/S.M./	Clair LUGNIER, "Cyclic nucleotide phosphodiesterase (PDE) superfamily: A new target for the development of specific therapeutic agents", PHARMACOLOGY & THERAPEUTICS, 109 (2006), pgs. 366-398		
/S.M./	Timothy J. MARTINS, et al., "Purification and Characterization of a Cyclic GMP-stimulated Cyclic Nucleotide Phosphodiesterase from Bovine Tissues", THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 257, No. 4, Issue of February 25, 1981, pgs. 1973-1979		
/S.M./	Kenneth A. MARTIN, et al., "Studies on Purification of Phosphodiesterase", JETTEROGENESIS, Vol. 3, No. 1, 1999, pgs. 1309-1314		
/S.M./	Takashi MIKI, et al., "Characterization of the cDNA and Gene Encoding Human PDE3B, the cGIP1 Isoform of the Human Cyclic GMP-Inhibited Cyclic Nucleotide Phosphodiesterase Family", GENOMICS, 36, 1996, pgs. 476-485		
/S.M./	Seiko MURASHIMA, et al., "Characterization of Particulate Cyclic Nucleotide Phosphodiesterases from Bovine Brain: Purification of a Distinct cGMP-Stimulated Isoenzyme", BIOCHEMISTRY, Vol. 29, 1990, pgs. 5285-5292		
/S.M./	Rena OBERNOTLE, et al., "The cDNA of a human lymphocyte cyclic-AMP phosphodiesterase (PDE IV) reveals a multigene family", GENE, Vol. 29, 1993, pgs. 239-247		
Examiner Signature	/Susanna Moore/	Date Considered	11/22/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Applicant's unique citation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to life (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 4 of 4

Complete If Known

Application Number	10/524,956
Filing Date	December 15, 2005
First Named Inventor	Martin HENDRIX, et al.
Art Unit	1624
Examiner Name	Susanna More
Attorney Docket Number	01-2113

NON PATENT LITERATURE DOCUMENTS

/S.M./	K. Hemender REDDY, et al., "Versatile synthesis of 6-alkyl/aryl-1H-pyrazolo[3,4-d]pyrimidin-4[5H]-ones", INDIAN JOURNAL OF CHEMISTRY, Vol. 31B, March 1992, pgs. 163-166	
/S.M./	Magnus ROENN, et al., "Palladium (II)-Catalyzed Cyclization Using Molecular Oxygen as Reoxidant", TETRAHEDRON LETTERS, Vol. 36, No. 42, 1995, pgs. 7749-7752	
/S.M./	Guy J. ROSMAN, et al., "Isolation and Characterization of human cDNAs encoding a cGMP-stimulated 3',5'-cyclic nucleotide phosphodiesterase", GENE, Vol. 191, 1997, pgs. 89-95	
/S.M./	P. SCHIMDT, et al., "A new synthesis of pyrazolo [3,4-d] pyrimidines having coronary dilation properties", HELVETICA CHIMICA ACTA, Volume XLV, fascicule V (1962) No. 189, pgs. 1620-1627	
/S.M./	Arne SCHOUSBOE, et al., "Role of CA ²⁺ and Other Second Messengers in Excitatory Amino Acid Receptor Mediated Neurodegeneration: Clinical Perspectives", CLINICAL NEUROSCIENCE, Vol. 4, 1997, pgs. 194-198	
/S.M./	Joachim ULIRCH, "Crystallization", KIRK-OTHEMER ENCYCLOPEDIA OF CHEMICAL TECHNOLOGY, August 16, 2002, 7 pages	
/S.M./	Anthony R. WEST, "Solid Solutions", Department of Chemistry University of Aberdeen, March 3, 1988, 3 pages	
/S.M./	Gordon M. VEDRANT, et al., "Crystalline Solids", ADVANCED DRUG DELIVERY REVIEWS, Vol. 46, 2000, pgs. 3-26	
/S.M./	Ji-Ye WEI, et al., "Molecular and Pharmacological Analysis of Cyclic Nucleotide-Gated Channel Function in the Central Nervous System", PROGRESS IN NEUROBIOLOGY, Vol. 56, 1998, pgs. 37-64	
/S.M./	Internet Article, "Dementia", Information from the Mental Health Foundation, March 19, 2008, 3 pages http://www.mentalhealth.org.uk/information/mental-health-a-z/	
/S.M./	John R. BAKER, et al., "Chemistry and Positive Inotropic Effect of Paltirone and Related Derivatives. A Novel Class of 2-Methylpyrimidones and Inotropic Agents", J. MED. CHEM. 1988, vol. 31, Pgs. 812-823	

Examiner Signature	/Susanna Moore/	Date Considered	11/22/2009
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of the form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

*note: only structures considered.